Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, A. H.
Right arrow Articles by Jodrell, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, A. H.
Right arrow Articles by Jodrell, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 38, 885-893
© 1996 The British Society for Antimicrobial Chemotherapy

other

Development of guidelines for gentamicin dosing

A. H. Thomsona,b,*, N. Duncanb, B. Silversteinb, S. Alcockc and D. Jodrelld

aClinical Pharmacokinetics and Biometrics Unit, University Dept of Medicine and Therapeutics Glasgow G11 6NT, UK bPharmacy Practice Unit Glasgow G11 6NT, UK cClinical Microbiology Department Glasgow G11 6NT, UK dBeatson Oncology Centre Glasgow G11 6NT, UK

Received 22 January 1996; returned 9 April 1996; accepted 18 June 1996

*Tel: +44-141-211-2022; Fax: +44-141-339-2800; E-mail: a.h.thomson{at}clinmed.gla.ac.uk

The performance of dosage guidelines for starting gentamicin therapy was evaluated prospectively in 50 patients with suspected or proven Gram-negative septicaemia and the results were compared with results from similar group of 50 patients for whom the guidelines were not followed. Peak concentrations were significantly higher when the guidelines were followed (7.2 (±1.9) mg/L vs 5.7 (±1.8) mg/L) but there was no difference in trough concentrations. Fifty-eight per cent of patients had both peak and trough concentrations within the target range (peak >5 mg/L, trough <2 mg/L) when doses were decided empirically; this increased to 96% when the guidelines were followed. However, use of the guidelines achieved peaks of >7 mg/L in only 56% of patients. A revised protocol with higher doses given less frequently was therefore developed and a prospective assessment of its performance indicated that satisfactory concentrations were obtained in 96% of patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Sato, Y. Tanigawara, M. Kaku, N. Aikawa, and K. Shimizu
Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3763 - 3769.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
K Barata, M Yoshida, R Hokao, S Imai, S Takahashi, E Harada, and A Maekawa
Differential toxicity expression of gentamicin in five-sixths nephrectomized rats assigned to three progressive stages of renal dysfunction -- establishment of a new screening approach
Human and Experimental Toxicology, February 1, 2001; 20(2): 100 - 110.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.